Neuroblastoma Drugs Market, By Route of Administration, By Type, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Neuroblastoma Drugs Market size was valued at USD 815.5 Million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

The most prevalent kind of cancer among newborns is neuroblastoma. The sympathetic nervous system's embryonic malignancy, which arises from the neuroblasts, is what causes the cancer. The malignancy spreads to the spinal cord, chest, or adrenal nerve tissues. Neuroblastoma is diagnosed before the age of five in over 90% of cases. In rare instances, prenatal ultrasounds may reveal the malignancy. The increased incidence of neuroblastoma and childhood cancer are the main causes of the neuroblastoma drug market's expansion. According to estimates, as of 2023, over 700 children in the US will receive a neuroblastoma diagnosis annually. Additionally, the neuroblastoma drugs market is expected to develop as a result of people's increased awareness of cancer diagnosis and treatment. In the upcoming years, it is anticipated that the growing number of incident instances that are age- and gender-specific will spur industry expansion.

Neuroblastoma Drugs Market- Market Dynamics

Rising Incidence of Neuroblastoma

One of the main driver driving the market expansion for neuroblastoma drugs is the rise in the disease's occurrence. Neuroblastoma diagnoses have increased noticeably in recent years, especially in juvenile populations. The need for sophisticated and successful therapeutic strategies has increased as a result of this incidence trend. Pharmaceutical firms and researchers are encouraged to step up their efforts in creating novel neuroblastoma medications as more cases are discovered due to enhanced diagnostic capabilities and more awareness, which supports the neuroblastoma drug market's expansion.

Neuroblastoma Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global Neuroblastoma Drugs Market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on the route of administration segmentation, the injectable category was predicted to show maximum market share in the year 2023

Based on end-user segmentation, the hospitals were the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroblastoma Drugs Market- Segmentation Analysis:

The Global Neuroblastoma Drugs Market is segmented on the basis of Route of Administration, Type, End-user, and Region.

Based on the route of administration, the neuroblastoma drugs market is segregated into Oral and Injectable. In 2023, the injectable category held a dominant market position in the worldwide neuroblastoma drugs market due to its effectiveness, ease, and capacity to administer precise amounts of neuroblastoma pharmaceuticals. Further bolstering the category growth are injectable formulations, which provide a dependable and straightforward administration route, guaranteeing quick absorption and bioavailability-particularly important in pediatric oncology.

By type, the market is divided into Chemotherapy, Immunotherapy, Bone Marrow Transplantation, Retinoid therapy, Surgery, and Others. Due to growing knowledge and research developments, immunotherapy shows promise for more lasting and effective results, and it is anticipated to record the highest compound annual growth rate (CAGR) during the neuroblastoma drugs market forecast period. Immunotherapy currently holds the largest market share worldwide. Furthermore, the segment is growing as a result of continuous clinical trials and cooperative efforts that strengthen immunotherapy's momentum and establish it as a game-changing strategy in the changing field of neuroblastoma treatment.

Neuroblastoma Drugs Market- Geographical Insights

Geographically, the Neuroblastoma Drugs Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the greatest market share for neuroblastoma drugs in 2023. This increase is ascribed to both the rise of neuroblastoma cases and the development of technologically advanced medications. According to estimates, the United States spent more than USD 190 billion on cancer treatment in 2015, and that amount is expected to rise to over USD 200 billion in 2020. Additionally, the neuroblastoma drugs market is expanding due to rising healthcare sector spending and the approval of orphan drugs for the neuroblastoma treatment. The industry is expected to rise as more people receive chemotherapy and medication therapies to prevent more complications from the illness.

The market for neuroblastoma drugs in Europe is anticipated to hold the second-largest share. The rising incidence of childhood cancer and rising cancer treatment costs are the main factors driving the market's expansion. Additionally, due to its site-specific activity and lack of cytotoxic effects on the body, anti-GD2, the first medication licensed for the treatment of neuroblastoma, is seeing tremendous demand. Furthermore, the region's growing infant population and the creation of cutting-edge, innovative treatments for neuroblastoma are driving the neuroblastoma drugs market expansion. In addition, greater knowledge about neuroblastoma diagnosis and treatment has made it possible to concentrate on novel tumour targets for the development of cancer medications using cell-mediated immunotherapy.

Neuroblastoma Drugs Market- Competitive Landscape:

The presence of various competitors operating on a worldwide and regional scale, such as Y-mabs Therapeutics, Inc., Bristol-Myers Squibb Company, MacroGenics Inc., AstraZeneca plc, Eli Lilly and Company, and others are the main reason for the high degree of fragmentation in the neuroblastoma drugs market. A wide range of businesses that each contribute to the overall dynamics of the market defines the competitive landscape. The competition for market share among existing industry giants, newcomers, and specialist solution providers is the cause of this fragmentation. The market for neuroblastoma drugs has seen major players use acquisition, collaboration, agreement, and product approval as important developmental tactics to expand their product portfolio. For instance, in May 2023, The Brazilian Health Regulatory Agency approved the commercialization of DANYELZA (naxitamab-gqgk) 40mg/10mL injection, according to Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical business. In Brazil, Adium Pharma S.A., a partner of Y-mAbs, will sell DANYELZA.

Recent Developments:

February 2023: The European Medicines Agency approved the proposed pediatric investigation plan for naxitamab, according to a statement released by commercial-stage biopharmaceutical startup Y-mAbs Therapeutics, Inc. The Pediatric Committee expressed a favourable judgment, which led to the conclusion. The indication addressed by the PIP, relapsed/refractory high-risk neuroblastoma, as well as osteosarcoma, are the conditions for which Y-mAbs is developing naxitamab.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROBLASTOMA DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Y-mabs Therapeutics, Inc.
Bristol-Myers Squibb Company
MacroGenics Inc.
AstraZeneca plc
Eli Lilly and Company
Recordati Group
Cellectar Biosciences, Inc.
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
United Therapeutics Corporation
Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Chemotherapy
Immunotherapy
Bone Marrow Transplantation
Retinoid therapy
Surgery
Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Homecare
Speciality Clinics
Other

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4423

1. Neuroblastoma Drugs Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Neuroblastoma Drugs Market Snippet by Route of Administration
- 2.1.2. Neuroblastoma Drugs Market Snippet by Type
- 2.1.3. Neuroblastoma Drugs Market Snippet by End-user
- 2.1.4. Neuroblastoma Drugs Market Snippet by Country
- 2.1.5. Neuroblastoma Drugs Market Snippet by Region
2.2. Competitive Insights

3. Neuroblastoma Drugs Key Market Trends

3.1. Neuroblastoma Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Neuroblastoma Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Neuroblastoma Drugs Market Opportunities
3.4. Neuroblastoma Drugs Market Future Trends

4. Neuroblastoma Drugs Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Neuroblastoma Drugs Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Neuroblastoma Drugs Market Landscape

6.1. Neuroblastoma Drugs Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Neuroblastoma Drugs Market - By Route of Administration

7.1. Overview
- 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 7.1.2. Oral
- 7.1.3. Injectable

8. Neuroblastoma Drugs Market - By Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
- 8.1.2. Chemotherapy
- 8.1.3. Immunotherapy
- 8.1.4. Bone Marrow Transplantation
- 8.1.5. Retinoid therapy
- 8.1.6. Surgery
- 8.1.7. Others

9. Neuroblastoma Drugs Market - By End-user

9.1. Overview
- 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
- 9.1.2. Hospitals
- 9.1.3. Homecare
- 9.1.4. Speciality Clinics
- 9.1.5. Others

10. Neuroblastoma Drugs Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Neuroblastoma Drugs Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Neuroblastoma Drugs Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.8. France
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.8.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.9. Italy
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.9.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.10. Spain
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.10.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.11. United Kingdom
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.12. Russia
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.13. Netherlands
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.14. Sweden
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Neuroblastoma Drugs Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.9. South Korea
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.9.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.10. Japan
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.10.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Neuroblastoma Drugs Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Neuroblastoma Drugs Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Neuroblastoma Drugs Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. Y-mabs Therapeutics, Inc.
- 11.2.2. Bristol-Myers Squibb Company
- 11.2.3. MacroGenics Inc.
- 11.2.4. AstraZeneca plc
- 11.2.5. Eli Lilly and Company
- 11.2.6. Recordati Group
- 11.2.7. Cellectar Biosciences, Inc.
- 11.2.8. Teva Pharmaceutical Industries Ltd.
- 11.2.9. Pfizer Inc.
- 11.2.10. United Therapeutics Corporation
- 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us